Ford to Move Some Lincoln Production From China to U.S. in 2030 
LG, Nvidia Expand AI Partnership With Humanoid Robots, AI Factories 
Paramount Skydance Clears Regulatory Hurdles for Warner Bros. Discovery Deal 
Bernstein Picks BYD and Xiaomi as Top China EV Stocks Despite Weaker Demand 
Antofagasta Shares Drop 5% as Miner Cuts 2026 Copper Production Forecast 
Anthropic Eyes $6B Decart AI Acquisition Ahead of Mega IPO 
Aviva First-Half Operating Profit Jumps 24% as Direct Line Deal Boosts Growth 
Bank of America to Buy Up to 49.9% Stake in Jio Credit for $1.92 Billion 
Pandora Shares Rise as Q2 Results Beat Forecasts, 2026 Outlook Raised 
Micron Stock Upgraded to Buy as New Street Sees $2 Trillion Valuation Potential 
SMIC Shares Rally as Q2 Profit Surges 262% on Strong Chip Demand 
Sanrio Shares Plunge as Q1 Profit Miss Overshadows Strong Sales 
Stripe, Advent Reportedly Pursue $53 Billion PayPal Takeover 
Super Micro Stock Jumps 19% as AI Server Demand Drives Strong 2027 Outlook 
Bill Ackman’s Pershing Square Returns to Netflix With Major New Stake 
Apple Develops China-Specific AI Model With Alibaba as Apple Intelligence Launch Nears 
Maersk Raises 2026 Earnings Outlook as Shipping Profits Beat Expectations 
Add as a preferred source on Google
Roche Holding AG agreed to buy Telavant Holdings for $7.1 billion. The Swiss healthcare firm that operates pharmaceuticals and diagnostics businesses worldwide announced on Monday, Oct. 23, that it will acquire the developer of a new treatment for inflammatory bowel diseases that Roivant Sciences and Pfizer Inc. own with a minority stake.
According to Reuters, Roche Holding will have the right to develop, produce, and commercially market Roivant Sciences and Pfizer's experimental antibody called the RVT-3101 under the terms. Roche is aiming to release this drug in the United States and Japan.
RVT-3101 in Phase 3 Trial
Roche reportedly said the RVT-3101 is a "promising" new therapy currently being developed to help patients suffering from inflammatory bowel disease, ulcerative colitis, and Crohn's disease. This bowel disease is part of a chronic gastrointestinal disorder group that affects about eight million people worldwide.
It was added that 80% of the patients are not experiencing lasting remission. Roche believes that the new RVT-3101 or TL1A antibody has a big potential to help treat other diseases. The pharma company said the drug is already close to phase 3 of the trial.
"Promising" New Treatment
"We strongly believe this novel TL1A directed antibody has the transformational potential to make a significant difference for patients living with inflammatory bowel disease and potentially other diseases," Roche Group's chief executive officer, Thomas Schinecker, said in a press release. "We are excited to add this promising new therapy in development to our portfolio and to make it available to patients as quickly as possible."
Roche's chief medical officer, who also serves as the company's head of global product development, further said, "The recent Phase 2b for RVT-3101 delivered the first long-term, robust dataset demonstrating improved clinical remission in the maintenance treatment phase and with this promising data, we believe that RVT-3101 has the potential to be the first therapy that offers both high efficacy and safety for people with inflammatory bowel disease and the convenience of an at-home, subcutaneous administration."
Photo by: Roche Media Library
